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 Description of the Disease and Epidemiology 
 Hidradenitis suppurativa (HS), also called “acne in-
versa” or “maladie de Verneuil,” is a painful, inflamma-
tory, debilitating skin disease with a chronic intermittent 
course. It typically presents after puberty with painful, 
deep-seated, inflamed lesions in the apocrine gland-
bearing areas of the body: most commonly the axillae, 
inguinal and anogenital regions  [1] . Population-based 
studies in European countries suggest a 1-year preva-
lence of HS of about 1% in the general population, with 
estimates ranging from 0.1 to 4% globally. HS common-
ly presents after puberty, with the average age of onset 
between 21 and 23 years of age, and is more common in 
women, with a female to male ratio between 2: 1 and 5: 1 
 [2, 3] . Associations have also been reported with other 
inflammatory diseases, such as inflammatory bowel dis-
ease  [4] , pyoderma gangrenosum  [5] , and polycystic ova-
ry syndrome  [6] .
 The exact pathogenetic mechanism of HS remains un-
clear. Potential causes are related to genetic, environmen-
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 Abstract 
 Hidradenitis suppurativa (HS) is a painful, inflammatory, de-
bilitating skin disease with a chronic intermittent course. The 
central pathogenetic event seems to be the occlusion of the 
hair follicle. HS has a 1-year prevalence of about 1%. It typi-
cally presents after puberty with painful, deep-seated, in-
flamed lesions in the apocrine gland-bearing areas of the 
body: most commonly the axillae, inguinal, and anogenital 
regions. HS has a high negative impact on patients’ quality 
of life even in patients with only limited disease burden, and 
the diagnosis of HS is often made with a long diagnostic de-
lay. In this practical short version we present diagnostic and 
therapeutic recommendations which are based on a system-
atic literature search as well as an informal expert consensus 
of Swiss dermatologists and dermatosurgeons. 
 © 2017 S. Karger AG, Basel 
 Received: March 29, 2017 
 Accepted after revision: May 11, 2017 
 Published online: July 7, 2017 
 Robert E. Hunger, MD, PhD 
 Department of Dermatology, Inselspital
Freiburgstrasse 34
 CH–3010 Bern (Switzerland) 
 E-Mail robert.hunger   @   insel.ch 
 © 2017 S. Karger AG, Basel 
 www.karger.com/drm 
 Hunger et al.
 
Dermatology 2017;233:113–119
DOI: 10.1159/000477459
114
tal, endocrine, and microbiological factors. For example, 
HS can sometimes follow an autosomal dominant pattern 
of inheritance  [7, 8] , and a total of 35–40% of patients re-
port a family history of the disease. Several studies have 
pointed to higher than average smoking rates among HS 
patients (70–90%), and the severity and course of HS are 
correlated with body mass index. Due to its typical onset 
during puberty, an endocrine component has been sug-
gested  [9] . Finally, with regards to a possible microbial 
cause, a number of bacteria have been isolated from HS 
lesions. However, it is unclear whether bacteria are caus-
al to disease pathogenesis or secondary, and hence infec-
tion is unlikely to be a primary causative factor  [10] . 
Based on histopathological examination of HS biopsies, 
it is generally proposed that HS is initiated due to occlu-
sion of the terminal hair follicle in response to hyperke-
ratinization, leading to nodule or cyst formation, and 
eventually a ruptured follicular epithelium, resulting in 
chronic inflammation with sinus and fistula formation 
and extensive dermal scarring  [10–14] . 
 Clinical Presentation and Diagnosis 
 HS is characterized by recurrent inflammation occur-
ring more than 2–3 times in the last 6 months in the in-
verse regions of the body, presenting with nodules, sinus 
tracts and/or scarring  [15] . The disease is most frequent-
ly localized in the axillary and inguinofemoral regions. 
The typical areas of involvement in males and females 
and their prevalence are listed in  Table 1  [16, 17] . In some 
cases atypical localizations on the ears, chest, and back are 
observed  [18] .
 The diagnosis of HS is usually made by clinical exam-
ination, and in most cases skin biopsies are not required. 
However, they may be useful to rule out a differential di-
agnosis with a gram-positive bacterial cause (e.g., furun-
cle or carbuncle). The diagnostic criteria are summarized 
in  Table 2 and rely on the 3 main features of HS as previ-
ously reported  [19] : 
 1. Typical anatomical location: axillae and inguinocrural 
regions – symmetrical lesions suggest systemic disease 
versus local infection.
 2. Relapses and chronicity.
 3. Typical lesions: deep-seated nodules (blind boils), 
comedones, and/or fibrosis.
 While there is no consensus among the outcome mea-
sures used for HS, the most widely used disease activity 
scores are the Hurley staging and the Sartorius scoring 
system  [20] . Hurley scoring is usually assigned to 3 stages:
 Stage I: abscess formation, single or multiple, without 
sinus tracts and cicatrization.
 Stage II: recurrent abscesses with tract formation and 
cicatrization, single or multiple, with widely separated le-
sions.
 Stage III: diffuse or near-diffuse involvement, or mul-
tiple interconnected tracts and abscesses across the entire 
area.
 Hurley stage I disease is most common (65% of cases), 
followed by stage II (31% of cases) and stage III (4% of 
cases)  [20] . 
 The Sartorius score is a dynamic scoring system cre-
ated by Sartorius et al.  [21, 22] and later modified. Indi-
vidual nodules and fistulas are counted, allowing a dy-
namic measurement of the clinical disease severity. 
 The diagnosis of HS is complicated due to the substan-
tial variability in its course, making treatment challenging 
and resulting in a wide heterogeneity in response to treat-
ment. It has been proposed that this might be due to un-
detected clinical subtypes of the disease. However, these 
subtypes have not yet been associated with distinct patho-
genic mechanisms or differential responses to therapy 
 [10] . Thus, future research will be required to untangle 
these differences in an effort to optimize treatment.
 Course and Burden of Disease 
 HS is a chronic relapsing disease. If not treated ade-
quately it may lead to serious complications such as bac-
terial infections, fistula formation, contractures and limb 
mobility limitations, squamous cell carcinoma, depres-
sion, anemia, malaise, and social impairment  [23] . In-
deed, it has been reported to prevent patients from work-
ing during disease flares  [24] , and the purulent discharge 
can produce an odor and stain clothing, resulting in social 
 Table 1.  Typical anatomical locations of lesions in hidradenitis 
suppurativa (HS) as described by Canoui-Poitrine et al. [17]
Male,
n (%)
Female,
n (%)
p
Axillae 55 (78.6) 154 (66.7) 0.06
Breast 1 (1.4) 52 (22.5) <0.001
Inguinofemoral 54 (77.1) 216 (93.5) <0.001
Buttocks 28 (40.0) 54 (23.4) 0.006
Perineal/perianal 36 (51.4) 76 (32.9) 0.005
 HS patients: n = 302 (232 female, 70 male). 
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stigma  [25] . Scarring can also cause considerable disabil-
ity  [20] . A recent study showed that the effect of HS on 
the Dermatology Life Quality Index (DLQI) was 5.77 ± 
4.59 (mean ± SD) for patients with Hurley stage I disease, 
13.1 ± 6.41 for patients with Hurley II, and 20.4 ± 6.67 for 
patients with Hurley III. This is very high compared to a 
wide spectrum of other dermatological diseases  [26] . For 
example, moderate to severe psoriasis has a mean DLQI 
reported at 12–13  [27] .
 Among patient-reported signs and symptoms, pain 
was reported by 85% of individuals with HS to be the most 
bothersome, followed by swelling/inflammation (20%) 
and sensitivity/tenderness (10%)  [28] .
 In addition to effects on quality of life, there is also a 
long diagnostic delay associated with HS. In one prospec-
tive survey study, the average patient delay in seeing a 
physician was 2.5 ± 5.0 years for individuals with HS com-
pared to 1.0 ± 4.3 years for individuals with psoriasis. The 
diagnostic delay was 7.2 ± 8.7 years in HS versus 1.6 ± 4.8 
years in psoriasis. Furthermore, individuals with HS typ-
ically see many more physicians than psoriasis patients 
prior to receiving their diagnosis  [29] .
 Risk Factors and Comorbidities 
 Among all risk factors for HS studied to date, the 
strongest correlation among biological factors is obesity, 
while the strongest environmental association is with 
smoking. Revuz et al.  [2] found an odds ratio (OR) of 4.42 
for obesity (BMI >30) and 12.55 for smoking compared 
to healthy controls. Another study by Miller et al.  [30] 
found an OR of 6.38 for obesity. In line with this, indi-
viduals with diabetes mellitus (OR = 5.74) and metabolic 
syndrome (OR = 3.89) also have a strong positive asso-
ciation with HS  [30] . Individuals with HS also suffer from 
a significantly higher rate of cardiovascular risk factors 
compared to healthy controls  [31] .
 With respect to disease progression, 5 risk factors were 
associated with an increased risk of progression from 
Hurley stage I to stage II or III in a retrospective study of 
846 Dutch individuals with HS. These included male gen-
der, disease duration, BMI, smoking pack-years, and le-
sion location (with axillary, inguinal, and mammary le-
sions having the highest OR)  [32] .
 In addition, mechanical irritation and friction may 
also trigger HS  [33, 34] , and the co-occurrence of HS with 
polycystic ovary syndrome, Crohn disease  [35] , and de-
pression is statistically significant  [36] .
 Treatment Options 
 Because smoking and obesity show the strongest cor-
relation with disease severity  [2] , there is a general con-
sensus that individuals with HS be advised and supported 
in the cessation of smoking and in reducing their body 
weight. Furthermore, loose-fitting clothing in order to 
avoid mechanical stress and friction is recommended. HS 
has a strongly negative impact on quality of life, including 
depression and problems with social integration. Al-
though there are no studies proving efficacy on HS dis-
ease course, psychosocial support measures should be 
considered.
 Clinical practice recommendations for medical treat-
ment are summarized in  Figure 1 . To avoid bacterial su-
perinfections and reduce inflammation, maceration and/
or topical disinfectants (e.g., triclosan, ammonium bitu-
minosulfonate) or topical antibiotics (e.g., clindamycin 
solution  [37] ) are suggested. Inflamed nodules may be 
injected with intralesional steroids. If topical agents are 
not sufficient, systemic antibiotics are typically given. 
Doxycycline (50–200 mg daily for 3–6 months) or rifam-
picin combined with clindamycin (each 300 mg twice 
daily  [38] ) for up to 3 months are suggested. Zinc gluco-
nate (3 × 30 mg daily) may be added in combination. If 
antibiotics are not sufficient or no longer effective, the 
 Table 2.  Diagnostic criteria for hidradenitis suppurativa (HS)
Primary positive diagnostic criteria
History 
Recurrent painful suppurating lesions more than 
2 – 3 times in the last 6 months
Involvement of: 
Axilla
Inguinofemoral area
Buttocks
Breast in women
Perineal/perianal area
Presence of:
Nodules (inflamed or noninflamed)
Sinus tracts (inflamed or noninflamed)
Abscesses, scaring
Follicular occlusion (comedones, fistula comedones)
Secondary positive diagnostic  criteria
His tory
Family history of HS
Microbiology
Negative swab
Presence of normal skin microbiota
 Hunger et al.
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Swissmedic-approved dose of adalimumab should be 
considered (160 mg at week 1, 80 mg at week 2, and there-
after 40 mg weekly)  [39] . Alternatively, a recent study 
showed improvements with systemic acitretin at a dosage 
of 0.2–0.5 mg/kg per day  [40] . Many other agents may be 
used in patients with refractory disease; these include 
dapsone (50–150 mg daily), metformin, systemic ste-
roids, or cyclosporine A. 
 Concerning surgical treatment, patients need to know 
about the increased rate of recurring disease in order to 
Topical disinfectants
HJWULFORVDQ
Topical antibiotics
HJFOLQGDP\FLQPJP/
$PPRQLXPELWXPLQRVXOIRQDWH
,QWUDOHVLRQDOVWHURLGV
7HWUDF\FOLQHV
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2SWLRQDOFRPELQDWLRQZLWK]LQFJOXFRQDWHPJïGD\
5LIDPSLFLQFOLQGDP\FLQ
ïPJHDFK
7U\DWOHDVWPRQWKV²FRQWLQXHLILPSURYHPHQWV
$FLWUHWLQ
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7HUDWRJHQ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²PJGD\
3UHWUHDWPHQWDVVHVVPHQWGHWHUPLQHJOXFRVH
 SKRVSKDWHGHK\GURJHQDVH*3'OHYHOV²
 FRQWUDLQGLFDWLRQ*3'GHÀFLHQF\
&RPSOLFDWLRQKHPRO\WLFDQHPLD 
0HWIRUPLQ
²PJGD\
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$QWL71)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Retinoids
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%LRORJLFV
 Fig. 1. Medical treatment options for hidradenitis suppurativa in Switzerland.  
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make an informed consent. Local excision of single le-
sions is only recommended in localized, well-circum-
scribed cases of Hurley I and II  [1] . In all other cases, wide 
scalpel or CO 2 laser excision of the skin, including parts 
of the fatty tissue of the whole area affected (axilla, ingui-
nal area, buttocks, etc.), should be considered  [1] . We rec-
ommend healing by secondary intention with or without 
partial closure and with or without negative pressure-as-
sisted healing. The exact surgical treatment plan is as in-
dividual as in conventional therapy and needs to be elu-
cidated in cooperation with the patient. Physiotherapy is 
crucial until the complete healing of the wound. 
 The treatment algorithm based on disease-specific pa-
thology is given in  Figure 2 . This algorithm recommends 
various treatment options based on both Hurley staging 
and disease-specific features: inflammatory burden, fol-
licular occlusion, persistency of lesions, and the chronic 
intermittent course of the disease. Indeed, treatment op-
tions for the inflammatory features of this disease versus 
the noninflammatory features have also been highlighted 
recently by others  [41–43] . Our algorithm shares simi-
larities with these, but provides more details on therapeu-
tic options based on further classification of HS disease-
specific pathology. 
Hurley I (mild) Hurley II (moderate) Hurley III (severe)
Antiseptic wash
,QÁDPPDWLRQ
Follicular
occlusion 
Persistent
lesions 
Chronicity
Rifampicin + clindamycin
Dapsone
Tetracyclines
Anti-TNF (adalimumab)
Topical antibiotics (clindamycin)
Tetracyclines
Intralesional steroids
Zinc gluconate
Anti-TNF (adalimumab)
Retinoids (acitretin)
Retinoids (acitretin)
Dapsone
TE + 1-degree closure
TE + 2-degree closure (+/– negative pressure 
wound therapy, +/– skin graft)
TE + partial closure
CO2 laser
 Fig. 2. Swiss expert panel treatment algorithm for hidradenitis 
suppurativa (HS). Avoid trigger factors: smoking, mechanical fric-
tion, weight, and shaving. Therapies for our algorithm were se-
lected on the basis of established clinical efficacy, tolerability, and 
potential for adverse effects. Disease progression should be evalu-
ated every 3 months, and for patients demonstrating inadequate 
disease control, progression through therapies should be followed. 
Adalimumab therapy is the only approved medication to treat ac-
tive moderate to severe HS (acne inversa) in adult patients with an 
inadequate response to a systematic antibiotic therapy and the only 
therapy with evidence level A. Despite there not being any pub-
lished evidence on combination therapy for HS, this may need to 
be considered based on disease course. TE, total excision.  
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 As all nonsurgical options in HS very often lead to a 
nonsatisfactory result, surgical intervention is quite com-
mon and required in many cases. However, there is a lack 
of clinical studies examining how medical treatment and 
surgery should be combined, or how combination thera-
pies should be used in general. We expect that these clin-
ical questions will be addressed with ongoing clinical 
studies in the near future, allowing clinicians to reliably 
control all types and stages of HS. 
 Key Message 
 Hidradenitis suppurativa is one of the most neglected chronic 
inflammatory skin diseases.
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